-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pulmonary hypertension is a serious complication of systemic lupus erythematosus, characterized by increased load after the right chamber, including pulmonary arterial compliance (PAC) and pulmonary vascular resistance.
role of THE PAC in predicting the prognosis of pulmonary hypertension associated with systemic lupus erythematosus is not yet clear.
a recent study published in Hypertension, a leading journal of cardiovascular medicine, looked at 120 patients diagnosed with systemic lupus-related pulmonary hypertension between February 2012 and December 2016.
the researchers analyzed the subjects' baseline clinical characteristics and hemodynamic parameters.
the baseline right post-astral load is layered according to PAC and pulmonary vascular resistance.
end of the study was a combination of mortality and clinical deterioration.
15 months (8.5-24.0), 49 (41%) subjects had an end event.
patients with PAC-lt;1.39 mL/mmHg had a 3.09 times higher risk of end-point events than those with a PAC of 1.39 mL/mmHg (95% CI was 1.54-6.20, P-0.001).
multivariable Cox regression analysis showed that the strated right post-astric load was the only independent predictor of the study endpoint (risk ratio was 2.009 (95% CI was 1.390-2.904) and P.lt;0.001).
patients with the highest post-right post-cardiotreloyny load (PAC.lt;1.39 mL/mmHg, pulmonary vascular resistance of 10.3 Wood units) had the highest risk of developing a study endpoint (2 x 6.10; P.lt;0.014).
results of this study show that PAC is a good predictor of mortality and clinical deterioration in patients with systemic lupus-related pulmonary hypertension.
in addition to pulmonary vascular resistance, PACs may be an effective tool for screening high-risk groups in these patients.
.